Dexcel Pharma Technologies Ltd. - 10 Nov 2022 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Reporting relationship: 10%+ Owner
Issuer ticker: ROIV
Reported as of: 10 Nov 2022
Net transaction value: +$20,000,000
SEC form: 4
Accepted by SEC: 14 Nov 2022, 07:40:35 UTC
Prior SEC filing: 26 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman

Key filing fact

Dexcel Pharma Technologies Ltd. filed Form 4 for Roivant Sciences Ltd. (ROIV) on 14 Nov 2022.

Key facts

This page summarizes Dexcel Pharma Technologies Ltd.'s Form 4 filing for Roivant Sciences Ltd. (ROIV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Nov 2022, 07:40.

Change

Previous filing in this sequence was filed on 26 Apr 2022.
Current net transaction value: +$20,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ROIV transaction

Common Shares

Purchase

Transaction value: $20,000,000
Shares: +4,000,000
Change %: +4%
Price: $5.00
Shares after: 102,849,443
Date: 10 Nov 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 4,684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.

Footnote F2

The common shares were purchased by Dexcel in a registered public offering on November 10, 2022.